Cisplatin-etoposide combination in adjuvant therapy for non-small cell lung cancer: A Brazilian experience.

e17530 Background: Adjuvant chemotherapy is generally recommended in most patients with resected non–small cell lung cancer (NSCLC), with some restrictions according to tumor stage and size. However, different cisplatin-doublets were used in phase III trials, and the best choice remains unclear. The purpose of this study is to describe the Brazilian National Cancer Institute (INCA) experience with the cisplatin-etoposide (Cis-Vp) combination in this situation, with special interest to survival data. Methods: We retrospectively evaluated the medical charts of patients receiving adjuvant treatment for NSCLC at INCA between 2004 and 2008. The primary outcome was overall survival (OS) and prognostic factors were analyzed using log-rank. Results: Fifty-one patients were included, all treated with Cis-Vp. Median age was 61 years (40-76), and 53% were female. Adenocarcinoma was the most frequently reported histological subtype (57%), while squamous cell carcinoma was detected in 33%. Forty percent of patients we...